Dyadic International, Inc. (Dyadic), a global biotechnology company, has entered into a collaboration with Syngene International Limited (Syngene), an integrated research, development, and manufacturing services company, to develop a Covid-19 vaccine candidate that can protect against the emerging variants of concern and which can be manufactured affordably, at very large scale, using Dyadic’s proprietary C1-cell protein production platform.

Like the expanded partnership previously announced with Medytox, Inc., to co-develop vaccines in the Republic of Korea and multiple Southeast Asian countries, Dyadic will work with Syngene to develop a vaccine candidate to immunize people against current and future variants of the Covid-19 virus.

Mahesh Bhalgat, COO, Syngene International stated, “We look forward to our collaboration with Dyadic to initially explore the development of a Covid-19 vaccine, and to further evaluate the potential of developing a differentiated vaccine platform based on Dyadic’s proprietary C1- cell line.”

Mark Emalfarb, Dyadic’s founder and chief executive officer, commented, “We will work with Syngene to further develop our proprietary and patented C-1 cell protein production platform for its use in developing and manufacturing safe and effective vaccines. If successful, such vaccines can be manufactured rapidly and affordably, in very large quantities. The global pandemic has only amplified the urgent need for vaccines. With Syngene, we believe we have the right partner to develop and produce a safe and effective vaccine candidate, in the quantities the world will need at an affordable price. As we demonstrated through our efforts with the Zoonosis Anticipation Preparedness Initiative (ZAPI) and with the Israel Institute for Biological Research (IIBR), our C1 gene expression platform may facilitate faster, more durable, and more affordable responses to emerging infectious diseases. To this end, our collaboration with Syngene is an appropriate follow-up to our partnership with Medytox in Korea and Southeast Asia, and we continue to explore similar arrangements in other geographies to help bring high volume, low-cost, next generation vaccine and drug manufacturing to parts of the world that need these resources most urgently.”

Syngene International Ltd. is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.